STOCK TITAN

Encompass Health (NYSE: EHC) director acquires 259 shares in awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Encompass Health Corp director Edward M. Christie III acquired 248 shares of Encompass Health common stock on July 16, 2026 at a weighted average price of $112.43 per share, plus 11 additional shares on July 15, 2026 from dividend-related awards and director fee deferrals, for a total of 259 shares and direct holdings of 9,345 shares.

Positive

  • None.

Negative

  • None.
Insider Christie Edward M III
Role Director
Type Security Shares Price Value
Grant/Award Encompass Health Common Stock 248 $112.43 $28K
Grant/Award Encompass Health Common Stock 11 $0.00 --
Holdings After Transaction: Encompass Health Common Stock — 9,345 shares (Direct)
Footnotes (1)
  1. Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment. The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on July 15, 2026. This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $112.40 to $112.43, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.
Shares acquired 16 July 2026 248 shares Non-derivative acquisition at weighted average $112.43 per share on July 16, 2026
Shares acquired 15 July 2026 11 shares Non-derivative acquisition associated with dividend-related award on July 15, 2026
Holding after transactions 9,345 shares Total Encompass Health common stock held directly by Edward M. Christie III after reported acquisitions
Common stock dividend $0.19 per share Dividend paid on Encompass Health common stock on July 15, 2026 used to calculate RSU credits
Closing price on dividend date $109.88 Closing price on July 15, 2026 used in restricted stock unit credit calculation
Purchase price range $112.40–$112.43 Range of market purchase prices for shares acquired via the deferred fee plan
restricted stock units financial
"additional restricted stock units are credited to each non-employee director's account"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Directors Deferred Stock Investment Plan financial
"The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan"
non-qualified deferral plan financial
"is a non-qualified deferral plan adopted and approved by the Board of Directors"
weighted average price financial
"This per share price is a weighted average price. These shares were purchased"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider share acquisitions did Encompass Health (EHC) director Edward M. Christie III report?

Edward M. Christie III acquired 248 shares of Encompass Health common stock on July 16, 2026 at a weighted average price of $112.43 per share, plus 11 shares on July 15, 2026 from dividend-related equity awards and director fee deferrals.

How many Encompass Health (EHC) shares does Christie hold after these transactions?

After these transactions, Christie directly holds 9,345 shares of Encompass Health common stock. This reflects cumulative director equity awards, dividend-linked credits and deferred-fee plan purchases, rather than an open-market trading program or a single large discretionary investment.

At what prices were Christie's Encompass Health (EHC) shares acquired?

The 248-share acquisition used a weighted average price of $112.43 per share, with individual trades ranging from $112.40 to $112.43. The 11-share award was tied to dividend-related credits rather than a cash purchase price.

What is the Directors Deferred Stock Investment Plan at Encompass Health (EHC)?

The Directors Deferred Stock Investment Plan is a non-qualified deferral plan, effective November 1, 2007, allowing non-employee directors to elect during 2025 to defer portions of 2026 fees. Deferred fees are used quarterly to buy Encompass Health stock, with dividends reinvested in additional shares.

How did Encompass Health (EHC) dividends affect Christie's recent equity awards?

On July 15, 2026 Encompass Health paid a $0.19 per share dividend, with a closing price of $109.88. These figures were used to credit additional restricted stock units and to reinvest dividends within the deferred stock plan, contributing to Christie's new equity awards.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Christie Edward M III

(Last)(First)(Middle)
9001 LIBERTY PARKWAY

(Street)
BIRMINGHAM ALABAMA 35242

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Encompass Health Corp [ EHC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Encompass Health Common Stock07/15/2026A11(1)A$09,097D
Encompass Health Common Stock07/16/2026A248(2)A$112.43(3)9,345D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
2. The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on July 15, 2026.
3. This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $112.40 to $112.43, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.
/s/Patrick Darby, attorney-in-fact for Edward M. Christie, III07/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)